Corvus Pharmaceuticals Inc (FRA:C17)
€ 8.11 -0.01 (-0.12%) Market Cap: 547.60 Mil Enterprise Value: 504.48 Mil PE Ratio: 0 PB Ratio: 10.74 GF Score: 22/100

Corvus Pharmaceuticals, Inc. - Special Call Transcript

Feb 04, 2021 / 01:30PM GMT
Operator

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Corvus Pharmaceuticals Phase III Initiation Conference Call. (Operator Instructions) Please note this conference is being recorded.

I will now turn the conference over to your host, Matt Clawson from W2O Group. You may begin.

Matthew Clawson
W2O Group - Practice Lead of IR

Thank you, David, and good morning, everyone. Thank you for joining us for the Corvus Pharmaceuticals conference call to discuss the initiation of a COVID-19 Phase III clinical trial.

This call is also being webcast with presentation slides. We encourage participants to join the webcast in order to review the slides while we speak. You can find the link to join the webcast on the Investor Relations home page of the Corvus website.

Joining me on the call from the company this morning are Dr. Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; and Dr. Mehrdad Mobasher, Chief Medical Officer. The executive team will open the call with some prepared remarks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot